Efficacy of ß-lactam/ß-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-ß-lactamase-producing enterobacteriaceae in hematological patients with neutropenia

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 8, 2017, Pages

  Gudiol, Carlota ^a,b   Royo Cebrecos, Cristina ^a   Abdala, Edson ^c   Akova, Murat ^d   Álvarez, Rocío ^e   De La Calle, Guillermo Maestro ^f   Cano, Angela ^g,y   Cervera, Carlos ^h   Clemente, Wanessa T ⁱ   Martín Dávila, Pilar ^j   Freifeld, Alison ^k   Gómez, Lucía ^l   Gottlieb, Thomas ^m   Gurguí, Mercè ⁿ   Herrera, Fabián ^o   Manzur, Adriana ^p   Maschmeyer, Georg ^q   Meije, Yolanda ^r,y   Montejo, Miguel ^s   Peghin, Maddalena ^t   Rodríguez Baño, Jesús ^u   Ruiz Camps, Isabel ^v   Sukiennik, Teresa C ^w   Tebe, Cristian ^x   Carratalà, Jordi ^a,y   more..

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b Duran i Reynals Hospital   (Spain)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d HACETTEPE UNIVERSITY   (Turkey)

^e HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^f SCHOOL OF MEDICINE   (Spain)

^g UNIVERSITY OF CÓRDOBA   (Spain)

^h UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

ⁱ FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^j HOSPITAL RAMÓN Y CAJAL   (Spain)

^k UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^l HOSPITAL MÚTUA DE TERRASSA   (Spain)

^m Department of Microbiology and Infectious Diseases   (Australia)

ⁿ UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^o CEMIC   (Argentina)

^p Hospital Rawson   (Argentina)

^q CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^r Hospital of Barcelona   (Spain)

^s HOSPITAL DE CRUCES   (Spain)

^t S Maria Hospital   (Italy)

^u UNIVERSITY OF SEVILLE   (Spain)

^v HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^w Dermatology Service Santa Casa de Misericórdia de Porto Alegre Hospital Complex   (Brazil)

^x UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^y INSTITUTO DE SALUD CARLOS III   (Spain)

more..

Author keywords

Beta lactam beta lactamase inhibitors; Bloodstream infection; ESBLs; Mortality; Neutropenia

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM; CEFOPERAZONE PLUS SULBACTAM; ERTAPENEM; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOODSTREAM INFECTION; CASE FATALITY RATE; CATHETER INFECTION; DRUG EFFICACY; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; NEUTROPENIA; NEUTROPENIC ENTEROCOLITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; URINARY TRACT INFECTION; BACTEREMIA; COHORT ANALYSIS; COMPLICATION; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ENZYMOLOGY; METABOLISM; MICROBIOLOGY; MIDDLE AGED; MORTALITY;

ADULT; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; COHORT STUDIES; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA;

EID: 85026384016     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00164-17     Document Type: Article

References (23)

1. Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P, Fadda G, Leone G, Cauda R, Pagano L. 2009. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 58: 299-307. https://doi.org/10.1016/j.jinf.2009.02.002.
2. Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, Arnan M, Marin M, Carratalà J, Gudiol F. 2010. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: Clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 65:333-341. https://doi.org/10 .1093/jac/dkp411.
3. Kim SH, Kwon JC, Choi SM, Lee DG, Park SH, Choi JH, Yoo JH, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS. 2013. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: Factors associated with extended-spectrum -lactamase production and its impact on outcome. Ann Hematol 92: 533-541. https://doi.org/10.1007/s00277-012-1631-y.
4. Ha YE, Kang CI, Cha MK, Park SY, Wi YM, Chung DR, Peck KR, Lee NY, Song JH. 2013. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents 42: 403-409. https://doi.org/10.1016/j.ijantimicag.2013.07.018.
5. Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cisnal M, Sánchez-Ortega I, Duarte R, Calvo M, Carratalà J. 2011. Bacteraemia due to multidrugresistant Gram-negative bacilli in cancer patients: Risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 66:657-663. https://doi .org/10.1093/jac/dkq494.
6. Lin MY, Weinstein RA, Hota B. 2008. Delay of active antimicrobial therapy and mortality among patients with bacteremia: Impact of severe neutropenia. Antimicrob Agents Chemother 52:3188-3194. https://doi.org/10.1128/AAC.01553-07.
7. Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group. 2015. Carbapenemase-producing Enterobacteriaceae in Europe: Assessment by national experts from 38 countries, May 2015. Euro Surveill 20:pii-30062. https://doi.org/10.2807/1560-7917.ES.2015.20.45.30062.
8. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. 2010. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect Dis 10:597- 602. https://doi.org/10.1016/S1473-3099 (10)70143-2.
9. Hauck C, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Scalera NM, Doi Y, Kaye KS, Evans S, Fowler VG, Jr, Bonomo RA, van Duin D; Antibacterial Resistance Leadership Group. 2016. Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumonia infections. Clin Microbiol Infect 22:513-519. https://doi.org/10.1016/j.cmi.2016.01 .023.
10. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. 2012. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: Importance of combination therapy. Clin Infect Dis 55: 943-950. https://doi.org/10.1093/cid/cis588.
11. Satlin MJ, Cohen N, Ma KC, Gedrimaite Z, Soave R, Askin G, Chen L, Kreiswirth BN, Walsh TJ, Seo SK. 2016. Bacteremia due to carbapenemresistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. J Infect 73:336-345. https://doi.org/10.1016/j.jinf.2016.07 .002.
12. Satlin MJ, Calfee DP, Chen L, Fauntleroy KA, Wilson SJ, Jenkins SG, Feldman EJ, Roboz GJ, Shore TB, Helfgott DC, Soave R, Kreiswirth BN, Walsh TJ. 2013. Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma 54:799-806. https://doi.org/10.3109/10428194.2012.723210.
13. Shiber S, Yahav D, Avni T, Leibovici L, Paul M. 2015. Lactam/- lactamase inhibitors versus carbapenems for the treatment of sepsis: Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 70:41-47. https://doi.org/10.1093/jac/dku351.
14. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. 2012. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum -lactamases: A systematic review and meta-analysis. J Antimicrob Chemother 67:2793-2803. https://doi.org/10.1093/jac/dks301.
15. Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á; Extended- Spectrum Beta-Lactamases-Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. 2012. -Lactam/-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum -lactamase-producing Escherichia coli: A post hoc analysis of prospective cohorts. Clin Infect Dis 54: 167-174. https://doi.org/10.1093/cid/cir790.
16. Harris PN, Yin M, Jureen R, Chew J, Ali J, Paynter S, Paterson DL, Tambyah PA. 2015. Comparable outcomes for -lactam/-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae. Antimicrob Resist Infect Control 4:14. https://doi.org/10 .1186/s13756-015-0055-6.
17. Ng TM, Khong WX, Harris PN, De PP, Chow A, Tambyah PA, Lye DC. 2016. Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. PLoS One 11:e0153696. https://doi.org/10.1371/journal .pone.0153696.
18. Tsai HY, Chen YH, Tang HJ, Huang CC, Liao CH, Chu FY, Chuang YC, Sheng WH, Ko WC, Hsueh PR. 2014. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extendedspectrum -lactamase-producing Proteus mirabilis. Diagn Microbiol Infect Dis 80:222-226. .
19. Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, de Cueto M, Calbo E, Almirante B, Viale P, Oliver A, Pintado V, Gasch O, Martínez-Martínez L, Pitout J, Akova M, Peña C, Molina J, Hernández A, Venditti M, Prim N, Origüen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Giamarellou H, Almela M, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Mora-Rillo M, Natera C, Souli M, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J, the REIPI/ESGBIS/INCREMENT Group. 2016. A multinational, preregistered cohort study of -lactam/-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 60:4159-4169. https://doi.org/10.1128/AAC .00365-16.
20. Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE; Antibacterial Resistance Leadership Group. 2015. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum -lactamase bacteremia. Clin Infect Dis 60:1319-1325.
21. Ofer-Friedman H, Shefler C, Sharma S, Tirosh A, Tal-Jasper R, Kandipalli D, Sharma S, Bathina P, Kaplansky T, Maskit M, Azouri T, Lazarovitch T, Zaidenstein R, Kaye KS, Marchaim D. 2015. Carbapenems versus piperacillintazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Infect Control Hosp Epidemiol 36:981-985. https://doi.org/10.1017/ice .2015.101.
22. Gudiol C, Royo-Cebrecos C, Tebe C, Abdala E, Akova M, Álvarez R, Maestro-de la Calle G, Cano A, Cervera C, Clemente WT, Martín-Dávila P, Freifeld A, Gómez L, Gottlieb T, Gurguí M, Herrera F, Manzur A, Maschmeyer G, Meije Y, Montejo M, Peghin M, Rodríguez-Baño J, Ruiz- Camps I, Sukiennik TC, Carratalà J; for the BICAR study group. Clinical efficacy of -lactam/-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum -lactamaseproducing Enterobacteriaceae in hematological patients with neutropenia: Study protocol for a retrospective observational study (BICAR). BMJ Open, in press.
23. Clinical and Laboratory Standards Institute (CLSI). 2016. Performance standards for antimicrobial susceptibility testing; approved standard, 26th ed. CLSI supplement M100S. Clinical and Laboratory Standards Institute, Wayne, PA.